Pfizer and BioNTech Achieve Success in Analysis From Phase 3 Study
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study | Pfizer https://t.co/QG3mmtr2iP
— Carol Duff (@CarolDuff18) November 10, 2020
Health Editor’s Note: Pfizer and BioNTech’s COVID-19 vaccine was found to be 90% effective in people who did not have previous COVID-19 infection. Submission for Emergency Use Authorization (EUA) to the FDA is planned soon ( in the third week of November.) The vaccine was deemed effective for people who have not contracted COVID-19 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study……Carol
Carol graduated from Riverside White Cross School of Nursing in Columbus, Ohio and received her diploma as a registered nurse. She attended Bowling Green State University where she received a Bachelor of Arts Degree in History and Literature. She attended the University of Toledo, College of Nursing, and received a Master’s of Nursing Science Degree as an Educator.
She has traveled extensively, is a photographer, and writes on medical issues. Carol has three children RJ, Katherine, and Stephen – one daughter-in-law; Katie – two granddaughters; Isabella Marianna and Zoe Olivia – and one grandson, Alexander Paul. She also shares her life with her husband Gordon Duff, many cats, and two rescues.